Trends and Differences Among Three New Indicators of HIV Infection Progression

Overview

Journal Public Health Rep

Publisher Sage Publications

Specialty Public Health

Date 2015 Sep 2

PMID 26327725

Citations 4

Authors

Qian An

Ruiguang Song

Angela Hernandez

H Irene Hall

Affiliations

Soon will be listed here.

Abstract

Objective: This study proposes three indicators of, and assesses the disparities and trends in, the risk of HIV infection progression among people living with diagnosed HIV infection in the United States.

Methods: Using data reported to national HIV surveillance through June 2012, we calculated the AIDS diagnosis hazard, HIV (including AIDS) death hazard, and AIDS death hazard for people living with diagnosed HIV infection for each calendar year from 1997 to 2010. We also calculated a stratified hazard in 2010 by age, race/ethnicity, mode of transmission, region of residence at diagnosis, and year of diagnosis.

Results: The risk of HIV infection progression among people living with diagnosed HIV infection decreased significantly from 1997 to 2010. The risks of progression to AIDS and death in 2010 were higher among African Americans and people of multiple races, males exposed through injection drug use (IDU) or heterosexual contact, females exposed through IDU, people residing in the South at diagnosis, and people diagnosed in 2009 compared with white individuals, men who have sex with men, females with infection attributed to heterosexual contact, those residing in the Northeast, and those diagnosed in previous years, respectively. People aged 15-29 years had the highest AIDS diagnosis hazard in 2010.

Conclusion: Continued efforts are needed to ensure early HIV diagnosis as well as initial linkage to and continued engagement in HIV medical care among all people living with HIV. Targeted interventions are needed to improve health-care and supportive services for those with worse health outcomes.

Citing Articles

How likely is unmeasured confounding to explain meta-analysis-derived associations between alcohol, other substances, and mood-related conditions with HIV risk behaviors?.

Manandhar-Sasaki P, Ban K, Richard E, Braithwaite R, Caniglia E BMC Med Res Methodol. 2025; 25(1):62.

PMID: 40055588 PMC: 11887180. DOI: 10.1186/s12874-025-02490-9.

The factors associated with natural disease progression from HIV to AIDS in the absence of ART, a propensity score matching analysis.

Jia X, Xia Z, Shi N, Wang Y, Luo Z, Yang Y Epidemiol Infect. 2020; 148:e57.

PMID: 32089142 PMC: 7078576. DOI: 10.1017/S0950268820000540.

The Opioid Epidemic: Impact on Inflammation and Cardiovascular Disease Risk in HIV.

Hileman C, McComsey G Curr HIV/AIDS Rep. 2019; 16(5):381-388.

PMID: 31473903 PMC: 6814576. DOI: 10.1007/s11904-019-00463-4.

Trends and Disparities in Mortality and Progression to AIDS in the Highly Active Antiretroviral Therapy Era: Tennessee, 1996-2016.

Rebeiro P, Pettit A, Sizemore L, Mathieson S, Wester C, Kipp A Am J Public Health. 2019; 109(9):1266-1272.

PMID: 31318589 PMC: 6687251. DOI: 10.2105/AJPH.2019.305180.

Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs.

Parashar S, Collins A, Montaner J, Hogg R, Milloy M Curr Opin HIV AIDS. 2016; 11(5):507-513.

PMID: 27254749 PMC: 5055433. DOI: 10.1097/COH.0000000000000297.

References

Gray K, Tang T, Shouse L, Li J, Mermin J, Hall H . Using the HIV surveillance system to monitor the National HIV/AIDS Strategy. Am J Public Health. 2012; 103(1):141-7. PMC: 3518344. DOI: 10.2105/AJPH.2012.300859. View

Poundstone K, Chaisson R, Moore R . Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS. 2001; 15(9):1115-23. DOI: 10.1097/00002030-200106150-00006. View

Linley L, Prejean J, An Q, Chen M, Hall H . Racial/ethnic disparities in HIV diagnoses among persons aged 50 years and older in 37 US States, 2005-2008. Am J Public Health. 2012; 102(8):1527-34. PMC: 3464816. DOI: 10.2105/AJPH.2011.300431. View

Krawczyk C, Funkhouser E, Michael Kilby J, Vermund S . Delayed access to HIV diagnosis and care: Special concerns for the Southern United States. AIDS Care. 2006; 18 Suppl 1:S35-44. PMC: 2763374. DOI: 10.1080/09540120600839280. View

McDavid Harrison K, Kajese T, Hall H, Song R . Risk factor redistribution of the national HIV/AIDS surveillance data: an alternative approach. Public Health Rep. 2008; 123(5):618-27. PMC: 2496935. DOI: 10.1177/003335490812300512. View

McDavid Harrison K, Ling Q, Song R, Hall H . County-level socioeconomic status and survival after HIV diagnosis, United States. Ann Epidemiol. 2008; 18(12):919-27. DOI: 10.1016/j.annepidem.2008.09.003. View

Andersen R, Bozzette S, Shapiro M, St Clair P, Morton S, Crystal S . Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res. 2000; 35(2):389-416. PMC: 1089126. View

Althoff K, Gebo K, Gange S, Klein M, Brooks J, Hogg R . CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?. AIDS Res Ther. 2010; 7:45. PMC: 3022663. DOI: 10.1186/1742-6405-7-45. View

Shapiro M, Morton S, McCaffrey D, Senterfitt J, Fleishman J, Perlman J . Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999; 281(24):2305-15. DOI: 10.1001/jama.281.24.2305. View

10.

Althoff K, Gange S, Klein M, Brooks J, Hogg R, Bosch R . Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010; 50(11):1512-20. PMC: 2862849. DOI: 10.1086/652650. View

11.

Gifford A, Bormann J, Shively M, WRIGHT B, Richman D, Bozzette S . Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000; 23(5):386-95. DOI: 10.1097/00126334-200004150-00005. View

12.

Goujard C, Bernard N, Sohier N, Peyramond D, Lancon F, Chwalow J . Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003; 34(2):191-4. DOI: 10.1097/00126334-200310010-00009. View

13.

Bradley H, Hall H, Wolitski R, Van Handel M, Stone A, LaFlam M . Vital Signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011. MMWR Morb Mortal Wkly Rep. 2014; 63(47):1113-7. PMC: 5779517. View

14.

Babiker A, Peto T, Porter K, Walker A, Darbyshire J . Age as a determinant of survival in HIV infection. J Clin Epidemiol. 2001; 54 Suppl 1:S16-21. DOI: 10.1016/s0895-4356(01)00456-5. View

15.

Moore R, Keruly J, Chaisson R . Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr. 2004; 35(1):46-51. DOI: 10.1097/00126334-200401010-00006. View

16.

Lee L, Karon J, Selik R, Neal J, Fleming P . Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA. 2001; 285(10):1308-15. DOI: 10.1001/jama.285.10.1308. View

17.

Gordillo V, Del Amo J, Soriano V, Gonzalez-Lahoz J . Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS. 1999; 13(13):1763-9. DOI: 10.1097/00002030-199909100-00021. View

18.

Hall H, McDavid K, Ling Q, Sloggett A . Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001. Ann Epidemiol. 2006; 16(11):824-33. DOI: 10.1016/j.annepidem.2006.01.009. View

19.

Krawczyk C, Funkhouser E, Michael Kilby J, Kaslow R, Bey A, Vermund S . Factors associated with delayed initiation of HIV medical care among infected persons attending a southern HIV/AIDS clinic. South Med J. 2006; 99(5):472-81. PMC: 2761649. DOI: 10.1097/01.smj.0000215639.59563.83. View

20.

Hader S, Smith D, Moore J, Holmberg S . HIV infection in women in the United States: status at the Millennium. JAMA. 2001; 285(9):1186-92. DOI: 10.1001/jama.285.9.1186. View